title: Hypoxia-induced increased permeability of endothelial monolayers occurs through lowering of cellular cAMP levels.
abstract: Prolonged exposure to hypoxia, as at high altitude, results in increased vascular permeability that may be ameliorated by administration of glucocorticoids. To understand mechanisms underlying these observations, cultured bovine aortic and pulmonary artery endothelial cells (ECs) were subjected to hypoxia, and changes in monolayer permeability and adenosine 3',5'-cyclic monophosphate (cAMP) levels were assessed. Exposure of both types of cultured ECs to hypoxia (PO2 approximately 14 Torr) led to a time- and dose-dependent increase in monolayer permeability, as measured by diffusion of radiolabeled solutes, which was associated with a progressive decrease in EC cAMP levels from 60 to 15 pmol/mg protein, and a decrease in EC adenylate cyclase activity. The change in endothelial barrier function was prevented by addition of cAMP analogues. Pertussis toxin protected EC monolayers from hypoxia-mediated increase in permeability while maintaining cAMP levels and adenylate cyclase activity. Addition of dexamethasone to EC monolayers before or simultaneously with their incubation under hypoxic conditions blocked the hypoxia-mediated increase in monolayer permeability. Dexamethasone pretreatment also prevented the decline in cAMP and adenylate cyclase levels in oxygen-deprived cultures. These data indicate that hypoxia decreases EC barrier function by lowering adenylate cyclase activity and cellular cAMP levels. They suggest that dexamethasone may exert its protective effect, in part, by preventing the hypoxia-induced decline in adenylate cyclase activity, leading to an increase in cellular cAMP and maintenance of EC barrier function.
authors.affiliation: Department of Physiology, Columbia University, College of Physicians and Surgeons, New York, New York 10032.
authors.forename: S
authors.initials: S
authors.lastname: Ogawa
authors.forename: S
authors.initials: S
authors.lastname: Koga
authors.forename: K
authors.initials: K
authors.lastname: Kuwabara
authors.forename: J
authors.initials: J
authors.lastname: Brett
authors.forename: B
authors.initials: B
authors.lastname: Morrow
authors.forename: S A
authors.initials: SA
authors.lastname: Morris
authors.forename: J P
authors.initials: JP
authors.lastname: Bilezikian
authors.forename: S C
authors.initials: SC
authors.lastname: Silverstein
authors.forename: D
authors.initials: D
authors.lastname: Stern
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D003994:Bucladesine / Q000494:pharmacology; D002417:Cattle; D015687:Cell Hypoxia / Q000187:drug effects; D002463:Cell Membrane Permeability / Q000502:physiology*; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000031:analogs & derivatives / Q000494:pharmacology / Q000502:physiology*; D003907:Dexamethasone / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology*; D007444:Inulin / Q000378:metabolism; D007700:Kinetics; D011651:Pulmonary Artery; D011956:Receptors, Cell Surface / Q000378:metabolism; D018179:Receptors, Thrombin; D012709:Serum Albumin / Q000378:metabolism; D013012:Sorbitol / Q000378:metabolism; D013873:Thionucleotides / Q000494:pharmacology; D013917:Thrombin / Q000378:metabolism
chemical_list: D011956:Receptors, Cell Surface; D018179:Receptors, Thrombin; D012709:Serum Albumin; D013873:Thionucleotides; C050086:N(6)-benzoyl-cyclic AMP; C015929:8-((4-chlorophenyl)thio)cyclic-3',5'-AMP; D013012:Sorbitol; D003994:Bucladesine; D003907:Dexamethasone; D007444:Inulin; D000242:Cyclic AMP; D013917:Thrombin